Eri Banno
Impact in
- Oncology top 10%
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
-
- Lung Cancer Treatments and Mutations
Papers in
-
- Lung Cancer Treatments and Mutations 11
- Prostate Cancer Treatment and Research 4
-
- PI3K/AKT/mTOR signaling in cancer 7
- Gut microbiota and health 5
- Co-authors
- Marco A. De Velasco (18 shared papers)Hirotsugu Uemura (21 shared papers)Kazutoshi Fujita (20 shared papers)Kazuto Nishio (21 shared papers)Norio Nonomura (9 shared papers)Yosuke Togashi (13 shared papers)Koji Hatano (6 shared papers)Kazuko Sakai (20 shared papers)
- Journals
- Cancer Research (6 papers)Annals of Oncology (5 papers)International Journal of Oncology (4 papers)Cancer Science (3 papers)Molecular Cancer Therapeutics (2 papers)
- Partner nations
- JapanItalyUnited States
In The Last Decade
Eri Banno
37 papers receiving 615 citations
Peers
Comparison fields: 5 of 79
- Oncology 246
- Pulmonary and Respiratory Medicine 263
- Urology 44
- Cancer Research 92
- Molecular Biology 321
Countries citing papers authored by Eri Banno
This map shows the geographic impact of Eri Banno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eri Banno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eri Banno more than expected).
Fields of papers citing papers by Eri Banno
This network shows the impact of papers produced by Eri Banno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eri Banno. The network helps show where Eri Banno may publish in the future.
Co-authors
The 25 scholars most cited alongside Eri Banno, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 42 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 73 | |
| 2 | 2016 | 70 | |
| 3 | 2020 | 64 | |
| 4 | 2022 | 62 | |
| 5 | 2021 | 50 | |
| 6 | 2014 | 40 | |
| 7 | 2022 | 34 | |
| 8 | 2016 | 28 | |
| 9 | 2016 | 27 | |
| 10 | 2016 | 21 | |
| 11 | 2014 | 16 | |
| 12 | 2016 | 15 | |
| 13 | Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion. | 2015 | 15 |
| 14 | 2017 | 14 | |
| 15 | 2016 | 13 | |
| 16 | 2015 | 12 | |
| 17 | 2022 | 9 | |
| 18 | 2016 | 8 | |
| 19 | 2023 | 7 | |
| 20 | 2021 | 6 |
About Eri Banno
Eri Banno is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Oncology, Surgery and Pathology and Forensic Medicine, having authored 42 papers that have together received 618 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (11 papers), Bladder and Urothelial Cancer Treatments (8 papers), PI3K/AKT/mTOR signaling in cancer (7 papers), Cancer Mechanisms and Therapy (5 papers), Gut microbiota and health (5 papers), Urinary and Genital Oncology Studies (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Prostate Cancer Treatment and Research (4 papers). The work is most often cited by research in Oncology (246 citations), Pulmonary and Respiratory Medicine (263 citations), Urology (44 citations), Cancer Research (92 citations) and Molecular Biology (321 citations). Eri Banno has collaborated with scholars based in Japan, Italy and United States. Frequent co-authors include Marco A. De Velasco, Hirotsugu Uemura, Kazutoshi Fujita, Kazuto Nishio, Norio Nonomura, Yosuke Togashi, Koji Hatano, Kazuko Sakai, Makoto Matsushita and Yoshihiko Fujita. Their work appears in journals such as Cancer Research, Annals of Oncology, International Journal of Oncology, Cancer Science and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.